Severe COVID-19 Rates Low With Monoclonal Antibody Therapy During Delta Surge
Rates of severe disease low for high-risk patients with mild-to-moderate COVID-19 treated with antispike monoclonal antibodies
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.